CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Moxifloxacin Ophthalmic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01296542
NCT01296542Phase 4Completed
CompareCT.gov

A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification

Bucci Laser Vision Institute·interventional·Posted Feb 15, 2011·Updated Dec 8, 2020

In Brief

A Phase 4 clinical trial evaluating Moxifloxacin Ophthalmic and Besifloxacin Ophthalmic for Cataracts. Completed, enrolled 60 participants across 1 site.

Detailed Summary

To compare antibacterial efficacy of Besivance versus VIGAMOX for decreasing bacteria of the conjunctiva and lid margins in cataract patients prior to surgery after both 1 hour and 3 days of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.4 years ago

Interventions

Moxifloxacin Ophthalmicdrug

Besifloxacin Ophthalmicdrug